Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCKBR | P32239 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6064507 | 0.87 | CCKBR (0.63) | CCKBRMAPTRXFP1TP53MEN1 | |
| SCHEMBL6489556 | 0.85 | CCKBR (0.58) | CCKBRMEN1NPC1RAB9AKMT2A | |
| SCHEMBL6064921 | 0.83 | CCKBR (0.64) | CCKBRMEN1NPC1RAB9AKMT2A | |
| SCHEMBL6065076 | 0.83 | CCKBR (0.64) | CCKBRMEN1NPC1RAB9AKMT2A | |
| SCHEMBL6501963 | 0.83 | CCKBR (0.56) | CCKBRMAPTRXFP1TP53MEN1 | |
| SCHEMBL6158876 | 0.82 | CCKBR (0.64) | CCKBRMEN1NPC1RAB9AKMT2A | |
| SCHEMBL6161329 | 0.77 | CCKBR (0.55) | CCKBREPHX2HIF1AEPAS1 | |
| SCHEMBL6065068 | 0.77 | CCKBR (0.59) | CCKBRMEN1NPC1RAB9AKMT2A | |
| SCHEMBL6498774 | 0.76 | CCKBR (0.55) | CCKBRMEN1NPC1RAB9AKMT2A | |
| SCHEMBL6065049 | 0.76 | CCKBR (0.63) | CCKBREPHX2HIF1AEPAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7105558-B2 | Gastrin and cholecystokinin receptor lignads (iv) | THE JAMES BLACK FOUNDATION LIMITED (GB) | 2006-09-12 | — | — | US | disclosed |
| US-20030195237-A1 | Gastrin and cholecystokinin receptor lignads (iv) | JAMES BLACK FOUNDATION LIMITED (GB) | 2003-10-16 | — | — | US | disclosed |
| WO-2001085704-A1 | GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS (IV) | JAMES BLACK FOUNDATION LIMITED (GB) | 2001-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195237-A1 | Gastrin and cholecystokinin receptor lignads (iv) | CCKAR, CCKBR, GRPR | CCKBR 2/4885MAPT 4796/4885RXFP1 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.